Complex and uncommon EGFR Mutations in the Glans-Look database
Click on the drop-down buttons below for detailed treatment and survival information related to the following complex and uncommon EGFR mutations.
Biomarkers
Complex EGFR mutations
Exon 19 del & L858R
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
Cytotoxic then TKI
Gefitinib
11.57
PD
9.29
16.50
TKI only
Gefitinib
14.51
Death
13.02
15.11
TKI only
Gefitinib
40.79
Patient decline
26.78
41.92
TKI only
Gefitinib
4.40
PD
1.65
6.21
TKI then cytotoxic
Gefitinib
16.03
PD
15.74
20.20
Exon 19 del & L858Q
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI then cytotoxic
Gefitinib
8.56
PD
5.12
15.67
Exon 19 del, S768I, & V774M
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI then cytotoxic
Gefitinib
19.44
PD
7.40
28.03
G719A & E709K
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Icotinib
9.49
PD
8.07
35.64
G719A & S768I
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Gefitinib
22.45
PD
22.18
22.73
G719X & Exon 19 del
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Gefitinib
2.61
AE
N/A
22.15
G719X & L861Q
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
No Tx
None
N/A
N/A
N/A
N/A
Cytotoxic then TKI
Erlotinib
7.67
Patient decline
3.70
7.67
G719X & S768I
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Gefitinib
8.56
PD
8.56
8.83
TKI only
Afatinib
56.10
N/A
N/A
53.09
TKI only
Gefitinib
2.15
PD
2.15
3.24
TKI only
Gefitinib
32.86
PD/T790M
29.29
45.82
TKI only
Gefitinib
0.93
Death
1.06
1.06
TKI only
Afatinib
68.78
N/A
Ongoing
Ongoing
G719S & S768I
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Gefitinib
80.63
N/A
51.97
77.16
Uncommon EGFR mutations
Exon 20 Insertion
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
No Tx
None
N/A
N/A
N/A
N/A
No Tx
None
N/A
N/A
N/A
N/A
No Tx
None
N/A
N/A
N/A
N/A
Cytotoxic only
None
N/A
N/A
N/A
N/A
G719X
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI then cytotoxic
Gefitinib
1.82
PD
1.62
9.19
TKI only
Gefitinib
14.35
PD
10.41
25.06
TKI only
Gefitinib
1.42
Patient decline
N/A
3.67
TKI only
Gefitinib
42.31
PD
20.76
45.42
TKI only
Afatinib
7.97
PD
4.56
12.79
TKI only
Gefitinib
0.99
Patient decline
N/A
45.16
Cytotoxic then TKI/ICI
Erlotinib
16.13
PD
10.91
17.65
L861Q
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Gefitinib
3.01
PD
3.01
5.26
TKI only
Gefitinib
1.62
Toxicity
N/A
17.62
TKI only
Gefitinib
14.35
PD
9.19
15.44
TKI only
Afatinib
11.34
PD
11.17
14.98
TKI then cytotoxic
Gefitinib
3.94
PD
3.27
4.43
TKI then cytotoxic
Gefitinib
4.40
PD
4.17
10.41
TKI only
Gefitinib
1.72
Death
N/A
1.72
TKI only
Gefitinib
7.07
Patient decline
N/A
9.36
TKI only
Gefitinib
2.81
PD
2.55
3.47
No Tx
None
N/A
N/A
N/A
N/A
TKI only
Afatinib
0.93
Toxicity
N/A
7.64
S768I
Treatment and Order
Initial TKI
Duration of TKI (months)
TKI End Reason
Progression Free Survival (months)
Survival Past TKI Start (months)
TKI only
Gefitinib
10.68
PD
10.48
13.26